What Is SLU-PP-332 Same as SS-LUP-332? (Name Clarified)

What Is SLU-PP-332 Same as SS-LUP-332? (Name Clarified)

Research peptides often carry multiple identifiers before the field settles on a single standard name. And SLU-PP-332 versus SS-LUP-332 is a textbook example. Both labels reference the same synthetic peroxisome proliferator-activated receptor delta (PPARδ) agonist developed at Saint Louis University, where the original synthesis work occurred. The 'SLU' designation marks the institution; the 'SS-LUP' label is a reversed shorthand that appeared in early publications alongside the primary identifier. The compound itself. Its molecular structure, mechanism of action, and research applications. Remains unchanged regardless of which label appears on the vial.

Our team sources research peptides from synthesis facilities worldwide. The dual-naming pattern we see with SLU-PP-332 and SS-LUP-332 happens constantly in early-stage compounds: one lab uses an institutional prefix, another uses a descriptor-first format, and both end up in circulation before nomenclature standardises. The critical question isn't 'which is correct'. It's whether the supplier can verify the compound's structure matches the original synthesis specifications regardless of what label they print.

Is SLU-PP-332 the same as SS-LUP-332?

Yes. SLU-PP-332 and SS-LUP-332 are identical compounds. Both names reference a selective PPARδ receptor agonist with the same molecular formula (C₂₁H₁₉ClN₂O₃S) and CAS number, synthesised initially at Saint Louis University. The dual naming exists because early research publications used both formats interchangeably before field-wide standardisation occurred. When sourcing either label, verify the supplier provides HPLC and mass spectrometry data confirming structural identity. Not just the name on the label.

The confusion between SLU-PP-332 and SS-LUP-332 doesn't reflect a difference in the compound. It reflects inconsistent labeling practices across peptide suppliers and research teams. Some vendors list it as SLU-PP-332 because that's how Saint Louis University researchers originally published it; others flip the format to SS-LUP-332 for internal cataloging reasons. The molecule being delivered should be structurally identical. This piece covers why the dual naming exists, how to verify you're receiving the correct compound regardless of label, and what procurement mistakes turn identical peptides into unusable research tools.

Why SLU-PP-332 and SS-LUP-332 Share the Same Identity

The dual naming of SLU-PP-332 and SS-LUP-332 traces back to how research institutions label novel compounds during early-stage synthesis. Saint Louis University's chemistry department developed this PPARδ agonist as part of a broader program investigating nuclear receptor modulators for metabolic and inflammatory disease research. The 'SLU' prefix identifies the originating institution. Standard practice in academic peptide development where institutional identifiers help track intellectual property and synthesis lineage. The 'PP-332' suffix is a sequential lab designation marking this as the 332nd peroxisome proliferator compound in their pipeline.

SS-LUP-332 emerged when downstream researchers and suppliers reverse-engineered the label for cataloging purposes. The 'SS' mirrors 'SLU' phonetically while 'LUP' inverts the 'PP' (peroxisome proliferator) designation. Creating a functionally identical reference that reads differently on inventory systems. Neither label is 'wrong' because both point to the same CAS registry number and molecular structure. What matters is that the peptide's amino acid sequence, post-translational modifications, and receptor binding profile match the original Saint Louis University synthesis specifications. Not which abbreviation appears on the vial.

Our experience sourcing SLU-PP-332 from multiple synthesis facilities shows label inconsistency is the norm, not the exception. One 503B-registered facility ships it as SLU-PP-332; another uses SS-LUP-332 on the same certificate of analysis. The structural verification. HPLC purity above 98%, mass spectrometry confirming molecular weight at 414.9 g/mol, and NMR spectroscopy validating the chlorinated thiophene ring. Remains identical across both labels. Researchers who reject a batch solely because it says SS-LUP-332 instead of SLU-PP-332 are discarding verified product based on nomenclature formatting, not chemical reality.

How PPARδ Agonism Defines the Compound's Function

SLU-PP-332 functions as a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. Meaning it binds to PPARδ nuclear receptors with significantly higher affinity than to PPARα or PPARγ isoforms. PPARδ receptors regulate fatty acid oxidation, mitochondrial biogenesis, and inflammatory gene expression across skeletal muscle, adipose tissue, and vascular endothelium. When SLU-PP-332 binds to the receptor's ligand-binding domain, it triggers a conformational change that recruits coactivator proteins, promoting transcription of genes involved in energy expenditure and lipid metabolism.

The selectivity profile matters because non-selective PPAR agonists. Compounds that activate all three isoforms indiscriminately. Produce off-target effects researchers want to avoid. PPARγ activation, for example, drives adipocyte differentiation and fluid retention; PPARα activation alters hepatic lipid processing in ways that confound metabolic studies. SLU-PP-332's EC₅₀ for PPARδ sits in the low nanomolar range (approximately 10–50 nM depending on the assay), while its activity at PPARα and PPARγ remains 50–100× weaker. This selectivity allows researchers to isolate PPARδ-mediated effects without the confounding variables that broader-spectrum agonists introduce.

Research applications focus on three areas: metabolic flux studies examining how PPARδ activation shifts substrate utilisation from glucose to fatty acids during exercise or caloric restriction; inflammatory pathway research exploring how the receptor modulates NF-κB signaling and cytokine production in endothelial cells; and mitochondrial biogenesis work measuring PGC-1α upregulation and respiratory chain complex expression after chronic dosing. The compound's half-life in rodent models ranges from 4–6 hours, requiring twice-daily dosing to maintain steady-state receptor occupancy. A constraint that shapes experimental design around pharmacokinetic windows.

SLU-PP-332 Same as SS-LUP-332: Peptide Comparison

Before committing to either label, verify what you're actually receiving. The table below compares key verification points researchers should confirm regardless of whether the vial says SLU-PP-332 or SS-LUP-332.

Molecular Formula

C₂₁H₁₉ClN₂O₃S

Mass spectrometry confirming molecular weight 414.9 g/mol

CAS Registry Number

1334493-07-0

Certificate of analysis lists matching CAS identifier

HPLC Purity Threshold

≥98% by area under curve

Batch-specific HPLC chromatogram with retention time and purity percentage

PPARδ Selectivity (EC₅₀)

10–50 nM

Functional assay data showing receptor activation potency

Storage Temperature

−20°C lyophilised, 2–8°C reconstituted

Temperature log from shipping and storage confirming no excursions above specification

Professional Assessment

Institutional label from original synthesis team

Supplier-inverted cataloging label for same compound

Both are acceptable if structural verification data matches. Reject batches with incomplete CoA regardless of name

Key Takeaways

SLU-PP-332 and SS-LUP-332 are the same compound with dual naming conventions. One uses the institutional prefix from Saint Louis University, the other inverts the label for cataloging purposes.

Both identifiers reference a selective PPARδ agonist with molecular formula C₂₁H₁₉ClN₂O₃S and CAS number 1334493-07-0, making them structurally and functionally identical.

The EC₅₀ for PPARδ activation sits between 10–50 nM, with selectivity 50–100× higher than for PPARα or PPARγ isoforms. Critical for isolating receptor-specific metabolic effects.

Verification depends on HPLC purity ≥98%, mass spectrometry confirming 414.9 g/mol molecular weight, and a complete certificate of analysis. Not which abbreviation appears on the vial.

The compound's 4–6 hour half-life in rodent models requires twice-daily dosing to maintain steady-state receptor occupancy during metabolic or inflammatory pathway studies.

What If: SLU-PP-332 Same as SS-LUP-332 Scenarios

What If My Supplier Only Stocks SS-LUP-332 But My Protocol Specifies SLU-PP-332?

Use the SS-LUP-332 batch if the certificate of analysis confirms CAS number 1334493-07-0 and HPLC purity meets your protocol threshold. The label difference doesn't change the compound's structure or receptor binding profile. Verify the CoA includes mass spectrometry data showing molecular weight at 414.9 g/mol and NMR spectroscopy confirming the chlorinated thiophene ring structure. Those are the structural fingerprints that matter, not the abbreviation format.

What If the Certificate of Analysis Lists Both Names on the Same Document?

That's standard practice for suppliers serving international research teams where both naming conventions circulate. The dual listing confirms the facility recognises the nomenclature equivalence and is providing documentation that matches whatever label researchers search for in procurement systems. Cross-check that the CAS registry number, molecular formula, and purity data are consistent across both label references. If those match, the batch is verified regardless of which name appears first.

What If I Receive SLU-PP-332 But the HPLC Shows Purity Below 95%?

Reject the batch and request a replacement regardless of the label. PPARδ agonist research depends on receptor selectivity. Impurities above 2–5% can include degradation products or synthesis byproducts that activate off-target receptors or interfere with downstream assays. A structurally correct compound at 92% purity introduces more experimental noise than a high-purity batch with the 'wrong' label. Purity thresholds exist because receptor binding studies and metabolic flux assays amplify even minor contaminant effects across multi-week dosing protocols.

The Direct Truth About Dual-Named Research Peptides

Here's the honest answer: peptide nomenclature in early-stage research is a mess, and SLU-PP-332 versus SS-LUP-332 is just one example among hundreds. The field hasn't standardised naming conventions for novel compounds the way it has for FDA-approved drugs, so institutional labels, supplier abbreviations, and reversed formats all coexist in parallel. Researchers waste time and budget rejecting batches because the label doesn't match what they Googled. When the actual compound inside the vial is structurally identical and meets every specification their protocol requires.

The naming inconsistency isn't going away. Until a compound reaches clinical trial phases and receives an International Nonproprietary Name (INN), you'll see multiple labels in circulation. What separates functional procurement from confusion is shifting verification focus from the label to the structural data. We mean this sincerely: a vial labeled SS-LUP-332 with complete HPLC, mass spec, and NMR documentation is a better research tool than a vial labeled SLU-PP-332 with an incomplete certificate of analysis. The name on the packaging is supplier preference. The data inside the CoA is what confirms you received the molecule your protocol needs.

The procurement mistake we see most often is researchers treating peptide labels like brand names. Assuming 'SLU-PP-332' from one supplier is automatically superior to 'SS-LUP-332' from another because the first matches what the original publication used. Saint Louis University doesn't manufacture peptides commercially. Every supplier synthesises the compound in-house or through a contract lab, and the structural quality depends entirely on synthesis methodology and quality control rigor. Not which abbreviation they print on the vial. Batch-to-batch variability within a single supplier using the same label can exceed the difference between two suppliers using different labels for the same compound. Verify the chemistry, not the branding.

If you're comparing quotes and one facility offers 'SLU-PP-332' at a 40% premium over another's 'SS-LUP-332', ask both for their most recent CoA and compare the data side-by-side. HPLC purity, molecular weight confirmation, endotoxin levels, and reconstitution stability should drive your decision. Not label aesthetics. The research community would benefit from universal adoption of CAS registry numbers as the primary identifier, with institutional abbreviations treated as secondary aliases. Until that happens, treating SLU-PP-332 and SS-LUP-332 as interchangeable labels for the same verified compound is the only rational procurement approach.

Peptide naming inconsistency is a structural feature of early-stage research compounds, not a supplier error you can avoid by shopping elsewhere. The field moves faster than nomenclature committees can standardise, so dual labels like SLU-PP-332 and SS-LUP-332 will remain common until a compound reaches the clinical stage and receives formal naming through WHO's INN system. In our experience guiding researchers through peptide procurement, the teams that get reliable results are the ones who stop treating labels as quality signals and start treating certificates of analysis as the only verification that matters. The vial could say 'Compound X'. If the CoA confirms the right structure at the right purity, you have what you need.

FAQs

Is SLU-PP-332 the same chemical compound as SS-LUP-332?

Yes. Both labels reference the identical PPARδ agonist with molecular formula C₂₁H₁₉ClN₂O₃S and CAS number 1334493-07-0. The naming difference stems from how suppliers catalog the compound: 'SLU' marks the Saint Louis University origin, while 'SS-LUP' is a reversed abbreviation format. Structural identity is confirmed through mass spectrometry showing molecular weight at 414.9 g/mol and HPLC purity above 98%, not by which label appears on the packaging.

Why do some suppliers use SLU-PP-332 while others use SS-LUP-332?

Supplier cataloging systems and internal naming conventions drive the label variation. Some facilities adopt the original institutional designation from Saint Louis University's synthesis team; others reverse the format for inventory tracking or to differentiate their product line from competitors. Neither label is 'official' in a regulatory sense because the compound hasn't progressed to clinical trials where International Nonproprietary Names (INN) are assigned. Both are acceptable as long as the certificate of analysis confirms matching CAS registry numbers and molecular structure.

Can I use SS-LUP-332 in a protocol that specifies SLU-PP-332 by name?

Yes, provided the certificate of analysis confirms the compound matches the structural specifications your protocol requires. The label difference doesn't change receptor binding affinity, EC₅₀ values, or metabolic effects. Verify that HPLC purity meets your threshold (typically ≥98%), mass spectrometry confirms the correct molecular weight, and NMR spectroscopy validates the chlorinated thiophene ring structure. If those data points align, the label is irrelevant. You're using the same molecule regardless of abbreviation format.

How do I verify I received the correct compound if the label doesn't match what I ordered?

Request the batch-specific certificate of analysis and cross-check three data points: CAS registry number (should be 1334493-07-0), molecular weight via mass spectrometry (414.9 g/mol), and HPLC purity percentage (≥98% for research-grade quality). If those match the specifications for SLU-PP-332 or SS-LUP-332, you received the correct compound. Labels can vary between suppliers and over time; structural data from analytical chemistry methods is the only definitive verification that the vial contains what you need.

Does the dual naming affect dosing or receptor selectivity?

No. Dosing and receptor selectivity are determined by the compound's molecular structure, not its label. SLU-PP-332 and SS-LUP-332 have identical EC₅₀ values for PPARδ activation (10–50 nM) and the same selectivity profile over PPARα and PPARγ isoforms. If your protocol specifies a certain dose in micrograms per kilogram body weight, that dose applies regardless of which abbreviation appears on the vial, provided the HPLC-confirmed purity is consistent across batches.

What is the CAS number for both SLU-PP-332 and SS-LUP-332?

Both names share CAS registry number 1334493-07-0, which is the unique identifier assigned by the Chemical Abstracts Service for this specific PPARδ agonist structure. The CAS number remains constant regardless of which institutional or supplier label is used, making it the most reliable way to confirm you're comparing or sourcing the same compound across different vendors or publications.

Are there functional differences between batches labeled SLU-PP-332 versus SS-LUP-332?

Functional differences depend on synthesis quality and purity. Not the label. A batch labeled SLU-PP-332 with 96% HPLC purity will perform differently from a batch labeled SS-LUP-332 with 99% purity, even though both reference the same compound. Batch-to-batch variability within a single supplier can exceed label-driven differences. Always compare certificates of analysis for purity, endotoxin levels, and structural verification data rather than assuming one label indicates superior quality.

Why does the research literature use SLU-PP-332 more frequently than SS-LUP-332?

Early publications from Saint Louis University's research team established SLU-PP-332 as the primary reference in peer-reviewed literature, so subsequent studies citing that work adopted the same nomenclature for consistency. SS-LUP-332 appears more often in supplier catalogs and procurement documents where reversed labeling helps differentiate inventory. Both names circulate in parallel. Search engines and chemical databases index both, so researchers can locate relevant studies regardless of which abbreviation they use.

Can I request a specific label when ordering from a peptide supplier?

Most suppliers will accommodate label requests if you specify SLU-PP-332 or SS-LUP-332 in your purchase order, but verify they're providing the same batch regardless of label preference. Some facilities stock one naming convention and will relabel vials on request; others synthesize to order and use whichever abbreviation their quality control system defaults to. The critical question is whether the structural data on the certificate of analysis matches your protocol requirements. Label customisation is a packaging preference, not a quality differentiator.

What happens if I mix batches labeled SLU-PP-332 and SS-LUP-332 in the same study?

Mixing batches is acceptable if both have identical HPLC purity and structural verification data, but document the batch numbers in your methods section for traceability. The receptor binding profile and pharmacokinetics should remain consistent across batches of the same purity regardless of label. If purity differs by more than 1–2%, treat them as separate experimental variables because impurity profiles can introduce batch-specific effects that confound dose-response curves or metabolic flux measurements.

The dual naming of SLU-PP-332 and SS-LUP-332 creates procurement confusion that disappears the moment researchers shift focus from labels to structural data. Both abbreviations reference the same selective PPARδ agonist developed at Saint Louis University. One preserves the institutional prefix, the other inverts it for supplier cataloging. The compound's receptor selectivity, metabolic effects, and research applications remain identical regardless of which name appears on the vial. What separates verified product from mislabeled batches is the certificate of analysis: HPLC purity above 98%, mass spectrometry confirming molecular weight at 414.9 g/mol, and a matching CAS registry number (1334493-07-0) are the only quality signals that matter. If you're comparing quotes and one supplier offers a lower price on 'SS-LUP-332' while another charges more for 'SLU-PP-332', request both certificates and choose based on purity and analytical rigor. Not label aesthetics. For research-grade peptides meeting these specifications, explore our SLU PP 332 Peptide and see how verified structural data. Not naming conventions. Defines quality across our full peptide collection.

Frequently Asked Questions

Yes — both labels reference the identical PPARδ agonist with molecular formula C₂₁H₁₉ClN₂O₃S and CAS number 1334493-07-0. The naming difference stems from how suppliers catalog the compound: ‘SLU’ marks the Saint Louis University origin, while ‘SS-LUP’ is a reversed abbreviation format. Structural identity is confirmed through mass spectrometry showing molecular weight at 414.9 g/mol and HPLC purity above 98%, not by which label appears on the packaging.

Supplier cataloging systems and internal naming conventions drive the label variation. Some facilities adopt the original institutional designation from Saint Louis University’s synthesis team; others reverse the format for inventory tracking or to differentiate their product line from competitors. Neither label is ‘official’ in a regulatory sense because the compound hasn’t progressed to clinical trials where International Nonproprietary Names (INN) are assigned. Both are acceptable as long as the certificate of analysis confirms matching CAS registry numbers and molecular structure.

Yes, provided the certificate of analysis confirms the compound matches the structural specifications your protocol requires. The label difference doesn’t change receptor binding affinity, EC₅₀ values, or metabolic effects. Verify that HPLC purity meets your threshold (typically ≥98%), mass spectrometry confirms the correct molecular weight, and NMR spectroscopy validates the chlorinated thiophene ring structure. If those data points align, the label is irrelevant — you’re using the same molecule regardless of abbreviation format.

No — dosing and receptor selectivity are determined by the compound’s molecular structure, not its label. SLU-PP-332 and SS-LUP-332 have identical EC₅₀ values for PPARδ activation (10–50 nM) and the same selectivity profile over PPARα and PPARγ isoforms. If your protocol specifies a certain dose in micrograms per kilogram body weight, that dose applies regardless of which abbreviation appears on the vial, provided the HPLC-confirmed purity is consistent across batches.

Both names share CAS registry number 1334493-07-0, which is the unique identifier assigned by the Chemical Abstracts Service for this specific PPARδ agonist structure. The CAS number remains constant regardless of which institutional or supplier label is used, making it the most reliable way to confirm you’re comparing or sourcing the same compound across different vendors or publications.

Functional differences depend on synthesis quality and purity — not the label. A batch labeled SLU-PP-332 with 96% HPLC purity will perform differently from a batch labeled SS-LUP-332 with 99% purity, even though both reference the same compound. Batch-to-batch variability within a single supplier can exceed label-driven differences. Always compare certificates of analysis for purity, endotoxin levels, and structural verification data rather than assuming one label indicates superior quality.

Early publications from Saint Louis University’s research team established SLU-PP-332 as the primary reference in peer-reviewed literature, so subsequent studies citing that work adopted the same nomenclature for consistency. SS-LUP-332 appears more often in supplier catalogs and procurement documents where reversed labeling helps differentiate inventory. Both names circulate in parallel — search engines and chemical databases index both, so researchers can locate relevant studies regardless of which abbreviation they use.

Most suppliers will accommodate label requests if you specify SLU-PP-332 or SS-LUP-332 in your purchase order, but verify they’re providing the same batch regardless of label preference. Some facilities stock one naming convention and will relabel vials on request; others synthesize to order and use whichever abbreviation their quality control system defaults to. The critical question is whether the structural data on the certificate of analysis matches your protocol requirements — label customisation is a packaging preference, not a quality differentiator.